Despite the large comorbidity between PTSD and opioid use disorders, as well as the common treatment of physical injuries resulting from trauma with opioids, the ability of opioid treatments to subsequently modify PTSD-related behavior has not been well studied.
Prescriptions for nonopioid pharmacological therapies such as gabapentin and baclofen have been increasing. While gabapentin and baclofen are less likely than opioids to result in fatal overdose, they are each associated with dependence, misuse and adverse effects.
A West Virginia University researcher is investigating whether an anti-itch medication that targets a specific part of our nerve cells can make morphine—which targets a different part—more effective.
The U.S. Department of Health and Human Services (HHS) announced more than $1.8 billion in funding to states to continue the Trump administration's efforts to combat the opioid crisis by expanding access to treatment and supporting near real-time data on the drug overdose crisis.
Despite known risks of using chronic opioid therapy (COT) for pain, the risks of discontinuation of COT are largely uncharacterized. The objective of this study was to evaluate mortality, prescription opioid use, and primary care utilization of patients discontinued from COT, compared with patients maintained on opioids.
AAPM Secretary W. Michael Hooten, MD comments on a new study on opioid and cannabis co-use, pointing out that the study shows us "that individuals with chronic pain who use opioids and cannabis concurrently are more likely to have mental health problems and other substance use issues, and that is very important." Dr. Hooten was not an author in the study.
AAPM member Beth B. Hogans, MD PhD comments in this NPR interview about the four-day course she helped create at Johns Hopkins for medical students about pain and pain management at the start of their medical education.
An Oregon committee has abandoned a controversial proposal that would have expanded treatment options for chronic pain patients under the Oregon Health Plan, but would have forced many to reduce dosages or discontinue prescription opioids.
The U.S. Food and Drug Administration (FDA) has received reports of serious harm in patients who are physically dependent on opioid pain medicines suddenly having these medicines discontinued or the dose rapidly decreased. These include serious withdrawal symptoms, uncontrolled pain, psychological distress, and suicide.
AAPM Past President Sean Mackey, MD PhD, co-authored a BMJ editorial on how the national pain strategies are part of the solution in managing this twin crises.
The opioid epidemic is no longer concentrated among whites in Appalachian and Midwestern states, according to a new study from Stanford, Harvard and the University of Toronto.
A four-week interdisciplinary pain management program for worker's compensation patients with chronic pain significantly reduced their opioid and benzodiazepine use, according to a new study.
Recent NIH study provides new insights concerning pain trends and opioid use for pain management.
What is the projected effect of lowering incident nonmedical prescription opioid use on the future trajectory of the opioid overdose crisis in the United States?